Simufilam

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Nov 7, 2022 → Jan 31, 2025

NCT ID

NCT05575076

About Simufilam

Simufilam is a phase 3 stage product being developed by Cassava Sciences for Alzheimer Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05575076. Target conditions include Alzheimer Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06390410	Phase 1	Completed	Jun 26, 2024	Dec 7, 2024	Hepatic Insufficiency
NCT06195319	Phase 1	Completed	Feb 7, 2024	Mar 27, 2024	Absorption
NCT05575076	Phase 3	Terminated	Nov 7, 2022	Jan 31, 2025	Alzheimer Disease
NCT05352763	Phase 2	Terminated	May 12, 2022	Dec 31, 2024	Alzheimer's Disease
NCT04932655	Phase 1	Completed	May 4, 2021	May 11, 2021	Healthy Volunteers

Competing Products

20 competing products in Alzheimer Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 2	21
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
Zagotenemab + Placebo	Eli Lilly	Phase 2	35
Donanemab + Placebo + LY3202626	Eli Lilly	Phase 2	35
Donanemab + Placebo	Eli Lilly	Phase 3	47
GSK4527226	Alector	Phase 2	29
AL002 + Placebo	Alector	Phase 2	25
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
donanemab	Eli Lilly	Phase 2	35
ATH-1017	LeonaBio	Phase 2/3	20
ATH-1017 + Placebo	LeonaBio	Phase 2/3	28
ATH-1017 + Placebo	LeonaBio	Phase 2	25
NDX-1017 + Placebo	LeonaBio	Phase 1	19
simufilam	Cassava Sciences	Phase 2	17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125	Cassava Sciences	Phase 1	19